Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Product Innovation Drives Continuous Flow Chemistry Market

Published: Friday, September 13, 2013
Last Updated: Friday, September 13, 2013
Bookmark and Share
Uniqsis celebrates five years of successful trading based on FlowSyn™ flow reactor systems.

Uniqsis Ltd has announced another strong year of international trading with particular growth in sales to organizations in the USA, France, Italy and China.

Launched in 2007 the company celebrates five years of successful trading, based on its renowned FlowSyn™ continuous flow reactor systems, in April 2013.

During this period, the company has not only developed the most comprehensive range of continuous flow chemistry equipment for the widest possible range of chemistries but has also established informed support for its customers throughout international markets.

Paul Pergande, Group MD of Uniqsis, commented “The key to our company’s success has been an unwavering commitment to product development and close collaboration with end users, research establishments and specialist technology partners”.

He added “Our first five years of trading as flow chemistry specialist have been both exciting and challenging. From day 1 we made it our priority to invest in new product development and to work closely with end users and specialist technology partners to help shape this dynamic new technology. Together with our partners we have worked hard to bring the widest possible range of high performance products to market as quickly as possible to meet increasingly complex and varied application needs, reaching as far as China, Japan, Australia and the USA. And the applications for continuous flow chemistry continue to grow, so we look forward to meeting the challenge of even more complex and varied chemistries in the coming years!”

At the heart of the Uniqsis product range is the FlowSyn™, a compact integrated continuous flow reactor system designed for easy, safe and efficient operation.

The FlowSyn™ range includes models for performing single or multiple homogeneous or heterogeneous reactions, either manually or automatically.

The range of chemistries that can be explored with Uniqsis’ integrated and modular flow chemistry systems grows ever wider and is exemplified by the growing number of applications published both in the academic press and in Uniqsis’ own application notes.

Typical examples of flow chemistry applications include hydrogenation, nitration, bromination, metalation, molecular rearrangements and synthesis of compounds such pyridine, indole, pyrazole and benzimidazole.

Whether users are new to flow chemistry or an advanced user, Uniqsis offer a comprehensive range of models with outstanding chemical compatibility and proven reliability, complemented by a full range of accessories to help users optimize their application.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cambridge Reactor Design and Uniqsis Announce Joint Marketing Agreement
The companies have entered into a joint marketing agreement for the Gastropod gas introduction module and the Polar Bear low temperature reactor, for flow chemistry applications.
Monday, April 18, 2011
Flow Chemistry Company Moves Ahead
Significant developments have been reported by Uniqsis to develop a new concept in flow chemistry, leading to the launch of the FlowSyn™ Continuous Flow Reactor at the end of last year.
Monday, January 14, 2008
Microreaction System Nears Launch
Uniqsis Ltd. has announced major progress towards launching FlowSyn™ later in the year.
Wednesday, August 15, 2007
Scientific News
Head Injury Patients have Protein Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
Exposure to Air Pollution 30 Years Ago Associated with Increased Risk of Death
Exposure to air pollution more than 30 years ago may still affect an individual's mortality risk today, according to new research from Imperial College London.
More Then 1 in 20 U.S. Children have Dizziness and Balance Problems
Researchers at NIH have found that girls have a higher prevalence of dizziness and balance problems compared to boys, 5.7 percent and 5.0 percent.
Biosensors on Demand
New strategy results in custom "designer proteins" for sensing a variety of molecules.
Low-Cost, Portable NQR Spectroscopy
A researcher at Case Western Reserve University is developing a low-cost, portable prototype designed to detect tainted medicines and food supplements that otherwise can make their way to consumers. The technology can authenticate good medicines and supplements.
Structure of Brain Plaques in Huntington's
Researchers at the University of Pittsburgh School of Medicine have shown that the core of the protein clumps found in the brains of people with Huntington's disease have a distinctive structure, a finding that could shed light on the molecular mechanisms underlying the neurodegenerative disorder.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Visualizing a Cancer Drug Target at Atomic Resolution
Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!